XJPX4896
Market cap49mUSD
Jan 17, Last price
661.00JPY
1D
0.30%
1Q
-13.82%
IPO
-23.32%
Name
K Pharma Inc
Chart & Performance
Profile
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is based in Minato, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY |
---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | |
Income | |||
Revenues | 1,000,000 | ||
Cost of revenue | 90,000 | 163,971 | |
Unusual Expense (Income) | |||
NOPBT | 910,000 | (163,971) | |
NOPBT Margin | 91.00% | ||
Operating Taxes | 40,746 | 1,900 | |
Tax Rate | 4.48% | ||
NOPAT | 869,254 | (165,871) | |
Net income | 260,330 -166.34% | (392,427) 71.58% | |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 1,496,325 | 1,544,375 | |
BB yield | -17.91% | ||
Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | 30,654 | 4,620 | |
Net debt | (3,266,408) | (1,336,847) | |
Cash flow | |||
Cash from operating activities | 454,425 | (363,482) | |
CAPEX | (9,803) | (29,958) | |
Cash from investing activities | (11,099) | (32,737) | |
Cash from financing activities | 1,486,235 | 1,544,285 | |
FCF | 869,652 | (166,269) | |
Balance | |||
Cash | 3,266,408 | 1,336,847 | |
Long term investments | |||
Excess cash | 3,216,408 | 1,336,847 | |
Stockholders' equity | 101,431 | 361,564 | |
Invested Capital | 3,033,991 | 977,420 | |
ROIC | 43.34% | ||
ROCE | 29.02% | ||
EV | |||
Common stock shares outstanding | 11,605 | 9,331 | |
Price | 720.00 | ||
Market cap | 8,355,312 | ||
EV | 5,088,904 | ||
EBITDA | 910,000 | (163,971) | |
EV/EBITDA | 5.59 | ||
Interest | 11,849 | ||
Interest/NOPBT | 1.30% |